Axinn Advised Thermo Fisher on $12.5B Acquisition of QIAGEN
March 3, 2020
Axinn represented Thermo Fisher Scientific Inc., the world leader in serving science, in its proposed $12.5 billion acquisition of QIAGEN N.V., a leading global provider of molecular diagnostics and sample preparation technologies. The Axinn antitrust team included partners John Harkrider, Michael Keeley, and Mark Alexander.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
AHLA Annual Meeting 2025
Speaking Engagement
Antitrust
SABA North America Annual Conference 2025
Speaking Engagement
Antitrust
Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
Webinar
Antitrust
Volunteer Lawyers for the Arts – Champions of the Arts Awards and Gala 2025
Sponsorship
Antitrust
Washington Lawyers’ Committee for Civil Rights and Urban Affairs – 2025 Wiley A. Branton Awards Luncheon
Sponsorship
Antitrust
Axinn Partners Named to WIPR's Leaders 2025 Directory
Awards & Recognitions
Intellectual Property
NJSBA Annual Meeting and Convention 2025
Speaking Engagement
Intellectual Property
Trump’s DOJ Stays the Course in Opposition to Shared Algorithmic Pricing
Byline Articles
Antitrust
Cost-Effective and Efficient IP Litigation Strategies – Making Paragraph IV Litigation Work for You
Webinar
Intellectual Property